News

HS-110 is the Company’s first product candidate in a series of proprietary ImPACT™ based immunotherapies designed to stimulate patient’s own T-cells to attack cancer. Additionally, as the FDA

VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed to treat patients recovering from non-elective hip fracture surgery. Investigators have dosed the initial subjects

GSK’s two manufacturing facilities in Australia, its opiate product portfolio and inventory will be transferred to Sun Pharma. The acquired business includes analgesics produced from raw materials found

The deal will expand Audentes’ portfolio with the addition of Cardiogen’s lead program for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). No therapies have yet been

A BACE (beta-site APP-cleaving enzyme-1) inhibitor program will be developed and commercialized in AD. The lead molecule will be Novartis’ oral therapy CNP520 drug and additional compounds from

The company scaled up manufacturing process for Laccure Pessary product. A search has been started for a company interested in acquiring Laccure and launching the product. Laccure CEO

The European Commission (EC) has granted marketing authorization for Strensiq, which treats the bone manifestation of pediatric-onset hypophosphatasia (HPP). Alexion said HPP is a genetic and progressive metabolic

The company previously received the first part of the award in March 2015 and successfully completed part one. Part two of the Fast-Track SBIR award totals $1.4 million

SGX942 is a first-in-class innate defense regulator (IDR) and is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck